Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.95 |
| ▸ | BLM | P54132 | 2/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | ESR1 | P03372 | 2/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.68 |
| ▸ | ABAT | P80404 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyramine SCHEMBL30831130 | 1.00 | TAAR1 (1.00) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL30831107 | 1.00 | TAAR1 (1.00) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL4111 | 1.00 | TAAR1 (1.00) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL31718804 | 0.97 | TAAR1 (0.95) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL32663617 | 0.97 | TDP1 (1.00) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL7742928 | 0.97 | TAAR1 (0.95) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL31738431 | 0.97 | TAAR1 (0.95) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL3950268 | 0.97 | TAAR1 (0.95) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL2121 | 0.97 | TDP1 (1.00) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 | |
| Tyramine SCHEMBL1804993 | 0.97 | TAAR1 (0.95) | TAAR1KDM4EADRA2ASLC6A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| CN-103893163-B | The application of 2-([1,1 '-biphenyl]-4-base) 2-oxoethyl 4-((the chloro-4-aminomethyl phenyl of 3-) is amino)-4-oxobutanoic acid esters in preparation LSD1 inhibitor medicaments | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2016-02-03 | — | — | CN | disclosed |
| CN-103893163-A | Application of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate in preparing an LSD1 (lysine-specific demethylase 1) inhibitor medicament | UNIV CHINA PHARMA | 2014-07-02 | — | — | CN | disclosed |
| EP-2588144-A2 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | Ventana Medical Systems, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2426139-A1 | CXCR4 antagonist and use thereof | Biokine Therapeutics Ltd. (IL) | 2012-03-07 | — | — | EP | disclosed |
| WO-2012003478-A2 | DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110269686-A1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
| US-8017585-B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2011-09-13 | — | — | US | disclosed |
| EP-2284209-A1 | POLYMER CONJUGATE OF FOLIC ACID OR FOLIC ACID DERIVATIVE | Nippon Kayaku Kabushiki Kaisha (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7888040-B2 | highly specific; methamphetamine, ecstacy, (+/-)-N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) and (+/-)-3,4-methylenedioxyethylamphetamine (MDEA); for use in the laboratory, point-of-care and on-site testing; without significant interference from other phenyethylamine derivatives | CONCATENO UK LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| CN-101259191-B | Fat-reducing health products and producing method thereof | NANNING SINOZYME BIOTECHNOLOGY CO LTD | 2010-12-29 | — | — | CN | disclosed |
| CN-101259191-A | Fat-reducing health products and producing method thereof | NANNING SINOZYME BIOTECHNOLOGY (CN) | 2008-09-10 | — | — | CN | disclosed |
| US-7423007-B2 | Cxcr4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2008-09-09 | — | — | US | disclosed |
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-23 | — | — | US | disclosed |
| US-6117996-A | COMPLEXING; SEPARATION; PURIFICATION OF PROTEINS | NOVO NORDISK A/S (DK) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | CXCR4, ACKR3, CXCR1 | TAAR1 1213/4885KDM4E 2945/4885ADRA2A 1038/4885 |
| US-20110269686-A1 | CXCR4 ANTAGONIST AND USE THEREOF | CXCR4, ACKR3, CXCR1 | TAAR1 1213/4885KDM4E 2945/4885ADRA2A 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.